Beth E. Arnold

Partner - Boston

Bio photo for Beth Arnold
Download Media Photo

Contact Information


617.832.7000 Download vCard

Beth Arnold, a partner in the firm’s intellectual property practice, is a U.S. registered patent attorney with close to 30 years of experience in obtaining worldwide patent protection for biopharmaceutical products. She has received recognition as a leading IP practitioner from Chambers USA (2005-2015), The Best Lawyers in America, Massachusetts SuperLawyers, Global Counsel 3000 and IP Stars. Her clients include top-tier public companies, private companies and medical research institutes. She has described by clients as "a force of nature in the biotech area in Boston" and a biotech patent attorney with "an impressive breadth and depth of experience." In addition to protecting intellectual assets, Beth prepares and negotiates agreements for developing and commercializing new products and technologies.

More »


  • Northeastern University School of Law, J.D.
  • Boston University, M.S. in Molecular Biology, cum laude
  • University of Rhode Island, B.S. in Biology, cum laude
  • Patent Considerations in Drug Development Agreements: 2012 and Beyond (May 2012)
  • A Practitioner's Guide to Petitions to Make Special, AIPLA Spring Meeting (May 11, 2005) 
  • Top five things to consider when negotiating an R&D partnership, MASS HIGH TECH (January 17-23, 2005)
  • Biogenerics may be inevitable, but will the feds be ready? BOSTON BUSINESS JOURNAL (March 2004)
  • Getting it Right the First Time: The Biomedical Patent Process, THE ART AND SCIENCE OF PATENT LAW (©Aspatore Books, Inside The Minds™ series) (2004)
  • Multiple patents, infringement cases add to cost of drugs, MASS HIGH TECH (March 2003)
  • Navigating Gene Patent Minefields, BIO IT WORLD (November 2002)
  • Potential Patent Obstacles on Horizon, BIO IT WORLD (August 2002)
  • Patenting Genes and Genetic Research Tools: Good or Bad for Innovation? ANNU. REV. GENOMICS HUM. GENET. 3:415-32 (2002)
  • Bioinformatic patents: Protecting path from data to drugs, BOSTON BUSINESS JOURNAL (June 2001)
  • Patent Strategies for Protecting Bioinformation: Consider Filing in Computer Examination Group, MIT FORUM REPORTER VOL.19 NO.6 (February 2001)
  • Chapter 2 - Patent Protection, BIOTECHNOLOGY: LAW, BUSINESS AND REGULATION, (Aspen Law & Business) (2000)
  • For Biotech Companies, IP Due Diligence Can Be Tricky, THE NATIONAL LAW JOURNAL (March 2000)

Foley Hoag Alerts & Updates


  • Listed in Best Lawyers in America in the field of  Litigation – Intellectual Property and Patent Law
  • Recognized in the 2013 MANAGING INTELLECTUAL PROPERTY's TOP 250 WOMEN in IP, a guide to the leading female intellectual property attorneys in the United States
  • Listed in MASSACHUSETTS SUPER LAWYERS (2004-2014)
  • Ranked by CHAMBERS USA: AMERICA'S LEADING LAWYERS FOR BUSINESS as one of Massachusetts' leading intellectual property lawyers (2004-2015)
  • Ranked as a “highly recommended” Life Sciences: Intellectual Property attorney in Boston by GLOBAL COUNSEL 3000 (2001-2005)


  • The Biotechnology Industry Organization (BIO), Member
  • The Massachusetts Biotechnology Council (MBC), Member
  • The Licensing Executive Society (LES), Member
  • American Intellectual Property Law Association (AIPLA), Member
  • Boston Patent Law Association (BPLA), Member
  • American Bar Association (ABA), Member
  • Boston Bar Association (BBA), Member


  • American Conference Institute (ACI) 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements: Allocating Rights, Responsibilities & Rewards in Licensing, Strategic Alliances and Partnering Deals, "Setting the Stage for Success by Choosing the Right Partner and Conducting Effective Due Diligence," November 13, 2008
  • AIPLA Spring Meeting, “A Practitioner’s Guide to Petitions to Make Special: How to Effectively Expedite Examination of Your Patent Application,” May 11, 2005
  • Springboard Enterprise Venture Capital Forum Alumni Celebration, “Partnering for Growth - Not Creating Competitors,” March 16, 2005
  • LES 40th Annual Meeting, “The Negotiation and Drafting of Collaborative Drug Development Agreements,” October 18, 2004
  • IBC Life Sciences Protecting Biotech Inventions Conference, “Patent Protecting Biological Processes in the U.S.,” Zurich Switzerland, September 21-23, 2004
  • MassMEDIC: Managing Your MedTech Company’s Intellectual Property, “Patent Claim Strategies to Maximize Value,” June 15, 2004
  • BioIT World 2004 Annual Meeting, Boston, MA, “The Druggable Genome: What to Patent?,” March 2004
  • The Licensing Executive Society (LES) Annual Meeting, Chicago, IL, “Patents and Biological Materials: Do You Really Own What You Think?”, September 2002
  • Compaq Computer Corporation and Whitehead Institute Center for Genome Research sponsored seminar, 21st Century Life Science Technology Revolution, “Patenting Genes and Genetic Research Tools,” June 10-12, 2002
  • Boston College Health Law Series, “Commercializing Medical Technologies,” October 2000
  • American Society of Law, Medicine & Ethics, Boston, MA, “The Impact of Patent Law on the Dissemination of Genetic Tests,” September 2000
  • McKinsey & Company Annual Healthcare Meeting, Boca Raton, FL, “Patent Considerations Pertaining to Genomic Technologies,” February 2000
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts

Court Admissions

  • U.S. Patent Trademark Office (Agency)
  • U.S. District Court for the District of Massachusetts